Hereditary hemorrhagic telangiectasia (HHT) is a vascular genetic rare disease (ORPHA: 774) characterized by systemic telangiectases and larger vascular malformations [1]. HHT can be diagnosed using either the Curaçao criteria or through molecular genetic testing. Curaçao criteria include: (i) recurrent epistaxis, (ii) mucocutaneous telangiectasia, (iii) visceral vascular malformations, and (iv), a first-degree family member with HHT [2]. The most common identifiable pathogenic variants associated with HHT are located in endoglin (ENG) or activin A receptor type II-like 1 (ACVRL1) genes and define HHT type 1 and type 2, respectively [2–5].
